Physician profile
Yubao Wang
NPI 1306942644
$3,646.53
in general payments reported to CMS, 2019-2025
49 companies · $1,811 in 2025
The $1,811 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $711 · 2020: $106 · 2021: $108 · 2022: $41.16 · 2023: $239 · 2024: $631 · 2025: $1,811.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,481 · Education: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,481.13 |
| Education | $199.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $402.39 | 2019-2025 | Erleada, Carvykti, Rybrevant |
| Merck Sharp & Dohme LLC | $244.88 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Novartis Pharmaceuticals Corporation | $236.19 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $230.55 | 2019-2025 | Krazati, Opdivo, Opdualag |
| Adaptive Biotechnologies Corporation | $137.40 | 2025 | Clonoseq |
| Astrazeneca Pharmaceuticals LP | $137.16 | 2019-2025 | Imfinzi, Tagrisso, Lynparza |
| Ipsen Biopharmaceuticals, INC | $131.60 | 2025 | Onivyde |
| Glaxosmithkline, LLC. | $121.59 | 2024-2025 | Ojjaara, Jemperli, Zejula |
| Asd Specialty Healthcare, LLC | $118.54 | 2019 | |
| Seagen INC. | $112.36 | 2021-2023 | Adcetris |
| Pfizer INC. | $110.10 | 2019-2025 | |
| Celgene Corporation | $104.08 | 2025 | Reblozyl |
| Genzyme Corporation | $103.66 | 2019-2024 | |
| Abbvie INC. | $102.64 | 2024-2025 | |
| Gilead Sciences, INC. | $101.99 | 2019-2024 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yubao Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.